<?xml version='1.0' encoding='utf-8'?>
<document id="19786507"><sentence text="Regulation of gene expression in brain tissues of rats repeatedly treated by the highly abused opioid agonist, oxycodone: microarray profiling and gene mapping analysis."><entity charOffset="95-101" id="DDI-PubMed.19786507.s1.e0" text="opioid" /><entity charOffset="111-120" id="DDI-PubMed.19786507.s1.e1" text="oxycodone" /><pair ddi="false" e1="DDI-PubMed.19786507.s1.e0" e2="DDI-PubMed.19786507.s1.e0" /><pair ddi="false" e1="DDI-PubMed.19786507.s1.e0" e2="DDI-PubMed.19786507.s1.e1" /></sentence><sentence text="Although oxycodone is the most often used opioid agonist, it remains one of the most understudied drugs"><entity charOffset="9-18" id="DDI-PubMed.19786507.s2.e0" text="oxycodone" /><entity charOffset="42-48" id="DDI-PubMed.19786507.s2.e1" text="opioid" /><pair ddi="false" e1="DDI-PubMed.19786507.s2.e0" e2="DDI-PubMed.19786507.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19786507.s2.e0" e2="DDI-PubMed.19786507.s2.e1" /></sentence><sentence text=" We used microarray analysis to better understand the global changes in gene expression in brain tissues of rats repeatedly treated with oxycodone"><entity charOffset="137-146" id="DDI-PubMed.19786507.s3.e0" text="oxycodone" /></sentence><sentence text=" Many genes were significantly regulated by oxycodone (e"><entity charOffset="44-53" id="DDI-PubMed.19786507.s4.e0" text="oxycodone" /></sentence><sentence text="g" /><sentence text=", Fkbp5, Per2, Rt1" /><sentence text="Dalpha, Slc16a1, and Abcg2)" /><sentence text=" Validation of the microarray data by quantitative real-time-polymerase chain reaction (Q-PCR) indicated that there was a strong significant correlation (r = 0" /><sentence text="979, p &lt; 0" /><sentence text="0000001) between the Q-PCR and the microarray data" /><sentence text=" Using MetaCore (a computational platform), many biological processes were identified [e" /><sentence text="g" /><sentence text=", organic anion transport (p = 7" /><sentence text="251 x 10(-4)) and regulation of immune response (p = 5" /><sentence text="090 x 10(-4))]" /><sentence text=" Among the regulated genes, Abcg2 mRNA was up-regulated by 2" /><sentence text="1-fold, which was further confirmed by immunoblotting (1" /><sentence text="8-fold up-regulation)" /><sentence text=" Testing the Abcg2 affinity status of oxycodone using an Abcg2 ATPase assay suggests that oxycodone behaves as an Abcg2 substrate only at higher concentrations (&gt; or = 500 microM)"><entity charOffset="38-47" id="DDI-PubMed.19786507.s19.e0" text="oxycodone" /><entity charOffset="90-99" id="DDI-PubMed.19786507.s19.e1" text="oxycodone" /><pair ddi="false" e1="DDI-PubMed.19786507.s19.e0" e2="DDI-PubMed.19786507.s19.e0" /><pair ddi="false" e1="DDI-PubMed.19786507.s19.e0" e2="DDI-PubMed.19786507.s19.e1" /></sentence><sentence text=" Furthermore, brain uptake studies demonstrated that oxycodone-induced Abcg2 up-regulation resulted in a significant (p &lt; 0"><entity charOffset="53-62" id="DDI-PubMed.19786507.s20.e0" text="oxycodone" /></sentence><sentence text="05) decrease (approximately 2-fold) in brain/plasma ratios of mitoxantrone"><entity charOffset="62-74" id="DDI-PubMed.19786507.s21.e0" text="mitoxantrone" /></sentence><sentence text=" These results highlight markers/mediators of neuronal responses and identify regulatory pathways involved in the pharmacological action of oxycodone"><entity charOffset="140-149" id="DDI-PubMed.19786507.s22.e0" text="oxycodone" /></sentence><sentence text=" These results also identify genes that potentially modulate tolerance, dependence, immune response, and drug-drug interactions" /><sentence text=" Finally, our findings suggest that oxycodone-induced up-regulation of Abcg2 enhanced the efflux of the Abcg2 substrate, mitoxantrone, limiting its brain accumulation and resulting in an undesirable drug-drug interaction"><entity charOffset="36-45" id="DDI-PubMed.19786507.s24.e0" text="oxycodone" /><entity charOffset="121-133" id="DDI-PubMed.19786507.s24.e1" text="mitoxantrone" /><pair ddi="false" e1="DDI-PubMed.19786507.s24.e0" e2="DDI-PubMed.19786507.s24.e0" /><pair ddi="false" e1="DDI-PubMed.19786507.s24.e0" e2="DDI-PubMed.19786507.s24.e1" /></sentence><sentence text=" Extrapolating these results to other Abcg2 substrates (e" /><sentence text="g" /><sentence text=", daunorubicin and doxorubicin) indicates that the brain uptake of these agents may be affected if they are administered concomitantly with oxycodone"><entity charOffset="2-14" id="DDI-PubMed.19786507.s27.e0" text="daunorubicin" /><entity charOffset="19-30" id="DDI-PubMed.19786507.s27.e1" text="doxorubicin" /><entity charOffset="140-149" id="DDI-PubMed.19786507.s27.e2" text="oxycodone" /><pair ddi="false" e1="DDI-PubMed.19786507.s27.e0" e2="DDI-PubMed.19786507.s27.e0" /><pair ddi="false" e1="DDI-PubMed.19786507.s27.e0" e2="DDI-PubMed.19786507.s27.e1" /><pair ddi="false" e1="DDI-PubMed.19786507.s27.e0" e2="DDI-PubMed.19786507.s27.e2" /><pair ddi="false" e1="DDI-PubMed.19786507.s27.e1" e2="DDI-PubMed.19786507.s27.e1" /><pair ddi="false" e1="DDI-PubMed.19786507.s27.e1" e2="DDI-PubMed.19786507.s27.e2" /></sentence><sentence text="" /></document>